Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance the degradation of this enzyme. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This mechanism positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2].